1. 1056PEstimated costs of treatment-related adverse events (TRAEs) for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the checkmate 141 trial. (18th September 2017) Authors: Venkatachalam, M.; Bobiak, S.; Shaw, J.W.; Santi, I.; Contente, M.; Korytowsky, B.; Stenehjem, D.D. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1222 Long-term clinical experiences of patients (pts) with non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) or metastatic melanoma (MEL): A SEER-Medicare analysis. (September 2015) Authors: Nadler, E.; Ashaye, A.; Stokes, M.; Yang, S.; Xu, Y.; Berger, A.; Shaw, J.W.; Gilloteau, I.; Abernethy, A.P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0379 Laboratory Safety of Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Rheumatoid Arthritis. (10th June 2014) Authors: Pappas, D.A.; Shaw, J.W.; Chang, H.; Cifaldi, M.A.; Reed, G.W.; Garg, V.; Lacerda, A.P.; Mozaffarian, N. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB1344 Hospital infusion center costs for anti–tumor necrosis factor agents. (23rd January 2014) Authors: Schmier, J.; Cifaldi, M.A.; Shaw, J.W.; Halpern, M.T.; Nickman, N.A. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 714 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CENTRAL CEILING AND ROOF SUPPORTS IN EARLY MINOAN II ARCHITECTURE. (7th April 2016) Authors: Shaw, J.W. Journal: Annual of the British School at Athens Issue: Number 111(2016) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FRI0153 Comparisons of work productivity and patient-reported outcomes through 78 weeks among optima study arms 2, 4, and 5. (23rd January 2014) Authors: Kavanaugh, A.F.; Emery, P.; van Vollenhoven, R.; Cifaldi, M.A.; Shaw, J.W.; Chen, N.; Smolen, J.S. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 362 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. FRI0156 Adalimumab treatment is associated with decreased concomitant RA medication use over 24 months. (23rd January 2014) Authors: Furst, D.E.; Mozaffarian, N.; Grant, S.; Cifaldi, M.; Clewell, J.; Kremer, J.; Shaw, J.W. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 364 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FRI0267 A Prediction Model That Identifies Patients Most Likely to Benefit from First-Line Therapy with Adalimumab plus Methotrexate in Early Rheumatoid Arthritis. (10th June 2014) Authors: van Vollenhoven, R.F.; Betts, K.; Signorovitch, J.; Bao, C.; Shaw, J.W.; Ganguli, A. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 480 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. FRI0412 Methodological issues when performing mixed treatment comparisons in rheumatoid arthritis: A sensitivity analysis. (23rd January 2014) Authors: Benedict, A.; Vanness, D.; Shaw, J.W.; Cifaldi, M.A. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 453 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. SAT0122 Efficacy of addition, or continuation, of adalimumab in patients who did not achieve stable low disease activity with methotrexate or adalimumab plus methotrexate in the optima study. (23rd January 2014) Authors: Kavanaugh, A.; Fleischmann, R.; Emery, P.; van Vollenhoven, R.; Florentinus, S.; Shaw, J.W.; Santra, S.; Kupper, H.; Redden, L.; Smolen, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 511 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗